RecruitingPhase 1NCT07066657

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: ArriVent BioPharma, Inc.
Intervention: MRG007(drug)
Enrollment: 405 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2030

Study locations (15)

ULCA, Los Angeles, California, United States
UCSF, San Francisco, California, United States
University of Colorado, Aurora, Colorado, United States
Sarah Cannon Research Institute, Denver, Colorado, United States
Sarah Cannon Research Institute, Sarasota, Florida, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
NEXT Dallas, Irving, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Peking University Cancer Hospital, Beijing, Beijing Municipality, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
Zhongshan Hospital Fudan University, Shanghai, Shanghai Municipality, China

Collaborators

Lepu Biopharma Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07066657 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia →

← Back to all trials